The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a ...

How Does Evenity Work for Osteoporosis? Throughout our lives, our bodies are constantly forming new bone and breaking down old bone. As we get older, the body begins to break down more bone than it ...

Amgen and UCB’s osteoporosis drug Evenity has finally won over the FDA, thanks to a pared-back indication in high-risk women. But the agency didn’t pass over the safety signal that torpedoed the drug ...

Amgen Inc. AMGN and Belgian partner UCB announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a negative opinion on the marketing ...

FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files By Deena Beasley (Reuters) - Amgen Inc ...

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures. The FDA announced Tuesday that the drug, called ...

In clinical trials, Evenity substantially increased bone density and prevented fractures more effectively than available treatments, according to the drug makers’ findings. By Gina Kolata The Food and ...

Amgen is pricing its newly approved osteoporosis drug Evenity on par with Radius Health’s competitor anabolic Tymlos. But its cardiovascular risk has already drawn outcry from a consumer activist ...

Dear Dr. Roach: My primary care doctor has prescribed the medication Evenity for my osteoporosis. I have been on Fosamax for about three years, but my recent bone density scan went down slightly in ...

(Reuters) - Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug ...

The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history ...